このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Shandong Pharmaceutical GlassLtd 将来の成長

Future 基準チェック /16

Shandong Pharmaceutical GlassLtd利益と収益がそれぞれ年間17.6%と12.6%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に13.2% 17.6%なると予測されています。

主要情報

17.6%

収益成長率

17.6%

EPS成長率

Medical Equipment 収益成長	22.4%
収益成長率	12.6%
将来の株主資本利益率	13.2%
アナリストカバレッジ	Good
最終更新日	20 May 2024

今後の成長に関する最新情報

Shandong Pharmaceutical Glass Co.Ltd Just Recorded A 18% EPS Beat: Here's What Analysts Are Forecasting Next

Apr 26

Recent updates

Calculating The Fair Value Of Shandong Pharmaceutical Glass Co.Ltd (SHSE:600529)

May 31

The Returns At Shandong Pharmaceutical GlassLtd (SHSE:600529) Aren't Growing

May 13

Shandong Pharmaceutical Glass Co.Ltd Just Recorded A 18% EPS Beat: Here's What Analysts Are Forecasting Next

Apr 26

業績と収益の成長予測

SHSE:600529 - アナリストの将来予測と過去の財務データ ( )CNY Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	7,087	1,362	N/A	1,598	6
12/31/2025	6,383	1,180	N/A	1,380	8
12/31/2024	5,609	999	N/A	1,096	8
3/31/2024	5,013	830	459	1,134	N/A
12/31/2023	4,982	776	376	1,048	N/A
9/30/2023	4,872	738	82	781	N/A
3/31/2023	4,382	632	-99	502	N/A
12/31/2022	4,187	618	-458	252	N/A
9/30/2022	4,058	616	-277	548	N/A
6/30/2022	4,040	612	-112	674	N/A
3/31/2022	3,991	588	25	773	N/A
12/31/2021	3,875	591	-59	750	N/A
9/30/2021	3,921	620	-55	676	N/A
6/30/2021	3,703	603	-206	551	N/A
3/31/2021	3,592	585	-243	445	N/A
12/31/2020	3,427	564	31	566	N/A
9/30/2020	3,147	532	-6	498	N/A
6/30/2020	3,093	503	89	594	N/A
3/31/2020	3,042	484	-53	596	N/A
12/31/2019	2,992	459	7	599	N/A
9/30/2019	2,821	437	-87	546	N/A
6/30/2019	2,720	409	-31	493	N/A
3/31/2019	2,651	386	124	492	N/A
12/31/2018	2,585	358	118	466	N/A
9/30/2018	2,546	326	245	485	N/A
6/30/2018	2,481	298	237	446	N/A
3/31/2018	2,400	281	187	349	N/A
12/31/2017	2,330	263	N/A	412	N/A
9/30/2017	2,314	259	N/A	349	N/A
6/30/2017	2,236	236	N/A	423	N/A
3/31/2017	2,181	216	N/A	461	N/A
12/31/2016	2,057	190	N/A	507	N/A
9/30/2016	1,860	162	N/A	478	N/A
6/30/2016	1,801	159	N/A	446	N/A
3/31/2016	1,758	152	N/A	465	N/A
12/31/2015	1,723	145	N/A	390	N/A
9/30/2015	1,771	141	N/A	440	N/A
6/30/2015	1,771	130	N/A	341	N/A
3/31/2015	1,717	127	N/A	293	N/A
12/31/2014	1,691	125	N/A	267	N/A
9/30/2014	1,653	117	N/A	282	N/A
6/30/2014	1,599	122	N/A	260	N/A
3/31/2014	1,577	121	N/A	286	N/A
12/31/2013	1,545	122	N/A	269	N/A
9/30/2013	1,519	126	N/A	164	N/A

アナリストによる今後の成長予測

収入対貯蓄率: 600529の予測収益成長率 (年間17.6% ) は貯蓄率 ( 2.9% ) を上回っています。

収益対市場: 600529の収益 ( 17.6% ) CN市場 ( 22.7% ) よりも低い成長が予測されています。

高成長収益: 600529の収益は増加すると予測されていますが、大幅には増加しません。

収益対市場: 600529の収益 ( 12.6% ) CN市場 ( 13.9% ) よりも低い成長が予測されています。

高い収益成長: 600529の収益 ( 12.6% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: 600529の自己資本利益率は、3年後には低くなると予測されています ( 13.2 %)。

Shandong Pharmaceutical GlassLtd 将来の成長

Future 基準チェック /16

主要情報

今後の成長に関する最新情報

Shandong Pharmaceutical Glass Co.Ltd Just Recorded A 18% EPS Beat: Here's What Analysts Are Forecasting Next

Price target decreased by 8.7% to CN¥33.37

Price target decreased to CN¥35.72

Price target decreased to CN¥35.72

Price target decreased to CN¥38.79

Recent updates

Dividend of CN¥0.40 announced

Shandong Pharmaceutical Glass Co.Ltd to Report First Half, 2024 Results on Aug 27, 2024

Calculating The Fair Value Of Shandong Pharmaceutical Glass Co.Ltd (SHSE:600529)

The Returns At Shandong Pharmaceutical GlassLtd (SHSE:600529) Aren't Growing

Shandong Pharmaceutical Glass Co.Ltd Just Recorded A 18% EPS Beat: Here's What Analysts Are Forecasting Next

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Shandong Pharmaceutical Glass Co.Ltd, Annual General Meeting, May 16, 2024

Shandong Pharmaceutical Glass Co.Ltd to Report Q1, 2024 Results on Apr 23, 2024

Investor sentiment improves as stock rises 16%

Shandong Pharmaceutical Glass Co.Ltd to Report Fiscal Year 2023 Results on Apr 23, 2024

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Second quarter 2023 earnings: EPS exceeds analyst expectations

Shandong Pharmaceutical Glass Co.Ltd to Report First Half, 2023 Results on Aug 29, 2023

Price target decreased by 8.7% to CN¥33.37

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Shandong Pharmaceutical Glass Co., Ltd announced that it has received CNY 1.866494692 billion in funding

Less than half of directors are independent

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Less than half of directors are independent

Triumph Science & Technology Co.,Ltd (SHSE:600552) cancelled the acquisition of a 11% stake in Shandong Pharmaceutical Glass Co., Ltd (SHSE:600529) from Shandong Luzhong Investment Co., Ltd.

Price target decreased to CN¥35.72

Investor sentiment improved over the past week

Price target decreased to CN¥35.72

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Less than half of directors are independent

Price target decreased to CN¥38.79

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.28 (vs CN¥0.26 in 3Q 2020)

Shandong Pharmaceutical Glass Co., Ltd announced that it expects to receive CNY 1.8664947 billion in funding

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS CN¥0.25 (vs CN¥0.21 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.26 (vs CN¥0.23 in 1Q 2020)

Investor sentiment deteriorated over the past week

New 90-day low: CN¥40.22

Market bids up stock over the past week

New 90-day low: CN¥42.42

Third-quarter earnings released: Revenue misses expectations

Third quarter earnings released

Shandong Pharmaceutical Glass Co., Ltd to Report Q3, 2020 Results on Oct 20, 2020

New 90-day low - CN¥45.11

First half earnings released

New 90-day high - CN¥67.10

Shandong Pharmaceutical Glass Co., Ltd to Report First Half, 2020 Results on Aug 18, 2020

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘